For non-diabetic users the question is whether both are needed: tirzepatide is far stronger for weight loss at 5 mg and above, while metformin is cheaper, oral, and more modest
Semaglutide remains the most effective pharmacological weight loss intervention available in 2026
Many patients in Miami begin noticing appetite changes within the first few weeks, with gradual weight loss over time under medical supervision
Obesity care, GLP-1s and the new equation for plan sponsors GLP-1s are transforming obesity care, and the decisions plan sponsors make will impact their organizations for years to come Daniel Cusator , MD, MBA, Account Medical Director, Blue Cross Blue Shield of Tennessee Shane Lipp , Senior Benefits Manager, Synovus Claire Morrow , PT, DPT, OCS, FAAOMPT, Physical Therapy Consultant Senior Manager, Hinge Health Charlie Smith , MD, Chief Medical Officer, AON Gabrielle Boisvert , Head of Solution Strategy, Teladoc Health (Moderator) In 2021, it was the beginning of the widespread, mainstream use of GLP-1s for weight loss
In human studies to date, there is no confirmed evidence that semaglutide causes thyroid cancer
10.1016/j.mcna.2023.06.001 34 LangerR